Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary cerebral hemorrhage with amyloidosis (HCHWA) describes a group of rare familial central nervous system disorders characterized by amyloid deposition in the cerebral blood vessels leading to hemorrhagic and non-hemorrhagic strokes, focal neurological deficits, and progressive cognitive decline eventually leading to dementia.
Biomarker and diagnostic research for cerebral amyloid angiopathy has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
13 clinical trials registered, 7 recruiting. Interventions under study include drug therapy, other interventions, and medical devices. Pipeline includes 1 PHASE3, 4 PHASE2, 1 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07250035](https://clinicaltrials.gov/study/NCT07250035) |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:13 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Jiedu Huayu Oral Prescription in the Treatment of Intracranial Hemorrhage Associated With Cerebral Amyloid Angiopathy |
PHASE3 |
Beijing Tiantan Hospital |
RECRUITING |
[NCT06714097](https://clinicaltrials.gov/study/NCT06714097) | Application of Digital Twins' Technology in Patients Who Had a Stroke, With Moyamoya Disease and With Cerebral Amyloid Angiopathy (CAA) During the Secondary Prevention Phase: A Proof of Concept Using a Randomized Control Trial (Clinical Study 6, STRATIF-AI Project) | NA | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | RECRUITING |
[NCT06933212](https://clinicaltrials.gov/study/NCT06933212) | Effect of the Mediterranean Diet in Patients Affected by CADASIL and Cerebral Amyloid Angiopathy. | — | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | RECRUITING |
[NCT05709314](https://clinicaltrials.gov/study/NCT05709314) | A Study of AMDX-2011P in Participants With CAA | PHASE2 | Amydis Inc. | RECRUITING |
[NCT04204642](https://clinicaltrials.gov/study/NCT04204642) | SEarchiNg biomarkErs Cerebral Amyloid Angiopathy (SENECA) | — | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | RECRUITING |
276 publications have been identified in PubMed for cerebral amyloid angiopathy. Research spans Review / Meta-Analysis (26%), Basic Science / Preclinical (26%), and Epidemiology / Natural History (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 60 | 26% |
Laboratory research | 60 | 26% |
Disease patterns and progression | 38 | 16% |
Testing and diagnosis research | 30 | 13% |
Patient case studies | 25 | 11% |
Other research | 10 | 4% |
Clinical study results | 8 | 3% |
New treatment approaches | 2 | 1% |
Zedde M (2026). [PMID: 41594629](https://pubmed.ncbi.nlm.nih.gov/41594629/). *Biomolecules*. [Review / Meta-Analysis]
You M (2026). [PMID: 41996885](https://pubmed.ncbi.nlm.nih.gov/41996885/). *J Prev Alzheimers Dis*. [Epidemiology / Natural History]
Chimal-Juárez E (2026). [PMID: 41724678](https://pubmed.ncbi.nlm.nih.gov/41724678/). *Alzheimers Dement*. [Basic Science / Preclinical]
Bax F (2026). [PMID: 42237156](https://pubmed.ncbi.nlm.nih.gov/42237156/). *Ann Neurol*. [Diagnostic / Biomarker]
Arndt P (2026). [PMID: 41532954](https://pubmed.ncbi.nlm.nih.gov/41532954/). *Ann Clin Transl Neurol*. [Basic Science / Preclinical]
Fastenau C (2026). [PMID: 40958354](https://pubmed.ncbi.nlm.nih.gov/40958354/). *Brain Pathol*. [Basic Science / Preclinical]
Theodorou A (2026). [PMID: 41614494](https://pubmed.ncbi.nlm.nih.gov/41614494/). *Eur Stroke J*. [Review / Meta-Analysis]
Su Y (2026). [PMID: 41580571](https://pubmed.ncbi.nlm.nih.gov/41580571/). *Acta Neuropathol*. [Case Report / Case Series]
Bugnon A (2026). [PMID: 41883280](https://pubmed.ncbi.nlm.nih.gov/41883280/). *Rev Med Suisse*. [Diagnostic / Biomarker]
Hu M (2026). [PMID: 40536954](https://pubmed.ncbi.nlm.nih.gov/40536954/). *Neural Regen Res*. [Diagnostic / Biomarker]
AI-curated news mentioning cerebral amyloid angiopathy
Updated Aug 31, 2026
A recent study identifies distinct characteristics and risk factors associated with symptomatic and incidental diffusion-weighted imaging (DWI) lesions in cerebral amyloid angiopathy. This research enhances understanding of the disease's clinical presentation and potential management strategies.
A recent study investigates the relationship between brain iron levels, cortical atrophy, and cognitive impairment in cerebral amyloid angiopathy. The findings utilize quantitative susceptibility mapping to enhance understanding of this condition.
A recent study investigates the relationship between amyloid PET burden, cerebrospinal fluid biomarkers, and APOE genotype in individuals with both iatrogenic and sporadic cerebral amyloid angiopathy. The findings contribute to understanding the underlying mechanisms of this condition.